Evidence map›Paper›PMID 41144043›Full record

ArticleNeurosurgical review2025

Nomogram for predicting new-onset visual symptoms after pipeline embolization device treatment in patients with ophthalmic artery aneurysms: a retrospective, multicenter study for model development and validation.

Huaying Xu, Linggen Dong, Dachao Wei, Jian Wang, Zizheng Wang, Chao Wang, Qichen Peng, Xiheng Chen, Mingtao Li, Yang Zhao and 2 more

Abstract readMulticenter StudyValidation Study
PubMed Publisher
In one paragraph

Article in Neurosurgical review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Huaying Xu *Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Linggen Dong *Department of Interventional Neuroradiology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Dachao WeiDepartment of Interventional Neuroradiology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Jian WangDepartment of Interventional Neuroradiology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Zizheng WangDepartment of Interventional Neuroradiology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Chao WangDepartment of Interventional Neuroradiology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Qichen PengDepartment of Interventional Neuroradiology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Xiheng ChenDepartment of Neurosurgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Mingtao LiDepartment of Neurosurgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Yang ZhaoDepartment of Neurosurgery, Peking University International Hospital, Peking University, Beijing, China.
Ming LvDepartment of Interventional Neuroradiology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China. dragontiger@163.com.
Yonghong JiaoBeijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China. yhjiao2001@aliyun.com.

Funding

National Natural Science Foundation of China 82271319
6 · The paper itself

Abstract

New-onset visual symptoms (NVS) are a significant complication after pipeline embolization device (PED) treatment for ophthalmic artery (OA) aneurysms, significantly impacting patients' quality of life. This study aimed to develop and validate a nomogram to predict the individualized risk associated with NVS in patients with OA aneurysms. This retrospective study included 669 patients with OA aneurysms treated with PEDs at four institutions from January 2016 to September 2024, with 506 in the training cohort and 163 in the validation cohort. OA was classified into Types 1-3 based on its anatomical relationship with aneurysms. Quantitative digital subtraction angiography assessed hemodynamic parameters changes pre- and post-PED treatment. Multivariate logistic regression identified predictors for nomogram construction. The predictive accuracy and clinical utility of the nomogram was evaluated using area under the curve (AUC), calibration curves, and decision curve analysis (DCA). The mean follow-up for the training cohort was 15.24 months, during which 45 patients (8.9%) developed NVS. Multivariate logistic regression identified age (OR,0.946, P = 0.001), type 3 OA origin (OR,3.699, P = 0.003), and Δ full width at half maximum-OA (OR,0.982, P = 0.020) as predictors for NVS. A nomogram incorporating these predictors yielded AUCs of 0.822 (95%CI, 0.765-0.879) and 0.807 (95%CI, 0.663-0.950) in the training and validation cohorts, respectively. The calibration curve and DCA analyses validate the nomogram's clinical utility. This study developed a novel nomogram to predict the risk of NVS following PED treatment in patients with OA aneurysms, offering valuable insights into preventing ophthalmic complications and improving patients' quality of life.

Indexed as

Embolization, TherapeuticIntracranial AneurysmNomogramsOphthalmic ArteryVision DisordersAdultAgedAngiography, Digital SubtractionFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeNew-onset visual symptomsNomogramOphthalmic artery aneurysmsPipeline embolization device

Identifiers

PMID41144043

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.